
|Videos|November 13, 2020
AAO 2020: Genentech provides update on presentations, product portfolio
Author(s)OT Staff Reports
Chris Brittain, MBBS, BSc, MBA, MRCOphth, vice president and global head of ophthalmology product development for Genentech, provides an overview of the company’s podium presentations from the PDS with ranibizumab to faricimab.
Advertisement
Chris Brittain, MBBS, BSc, MBA, MRCOphth, vice president and global head of ophthalmology product development for Genentech, provides an overview of some of the company’s podium presentations from the Port Delivery System with ranibizumab to the novel pipeline molecule, faricimab.
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Nanoscope Therapeutics releases positive long-term safety results from EXTEND study
2
Optigo: Lead anti-VEGF program advancing toward IND-enabling studies
3
Q&A: Sharon Fekrat discusses retinal manifestations of antipsychotic medications
4
Navigating the Gray Zone in MacTel Type 2: When to Treat Early or Advanced Disease
5

















































